US PTO reissue strengthens Pfizer's Lipitor patent
This article was originally published in Scrip
Pfizerhas completed an action to have the US Patent and Trademark Office reissue a patent related to its hypolipaemic, Lipitor. It will be referred to as reissue patent RE40667. The company applied for the reissue patent more than two years ago, in order to correct a technical defect in the '995 enantiomer patent for atorvastatin calcium, the salt form sold as Lipitor (expiring in June 2011).